Microbiome disruption in chronic rhinosinusitis: unraveling the role of dysbiosis

Chronic rhinosinusitis (CRS) is characterized by long-term inflammation of the nasal and sinus cavities, often associated with a disruption of the local microbiota, commonly referred to as dysbiosis. Recent advancements in culture-independent molecular techniques have expanded our understanding of how microbiome shifts contribute to the development and persistence of CRS. This condition is thought to result from a series of interconnected events, starting with impaired mucus clearance, which leads to the creation of anaerobic microenvironments that promote the growth of specific bacterial species capable of further exacerbating inflammation.

Research has highlighted a decrease in microbial diversity within the sinuses of CRS patients, with a shift towards anaerobic bacteria such as Peptoniphilus and Anaerococcus, which can thrive in the oxygen-limited conditions present in inflamed sinus tissues. This imbalance can result in the overgrowth of potential pathogens like Staphylococcus aureus and Pseudomonas aeruginosa, complicating treatment outcomes and leading to chronic disease progression. Moreover, viral and fungal communities, although less studied, are believed to interact with bacterial populations in complex ways, further influencing the course of CRS.

Emerging research suggests that interventions targeting microbial composition, such as probiotics and microbiota modulation, may offer novel therapeutic avenues. However, much remains to be understood about the exact role of these microbial communities in CRS, and further research is needed to develop effective, personalized treatment strategies that address both the dysbiotic microbiome and the resulting chronic inflammation.